BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ATX-101: Phase IIb data

Top-line data from a double-blind, dose-ranging, U.S. Phase IIb trial in 129 patients showed that ATX-101 met the co-primary endpoints of significantly improving CR-SMFRS and PR-SMFRS scores from baseline to 3 months post-treatment vs. placebo (p<0.05 for both). ATX-101 also met the secondary endpoints of significantly improving an...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >